CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s variation to produce Myozyme® (alglucosidase alfa) at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. The positive CHMP opinion is the final step before formal approval to produce and market Myozyme manufactured at the 4000 L bioreactor scale in the European Union, Norway and Iceland.
To read full press release from Genzyme, please click here (PDF, 15 kB)